Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study
Background. Litramine (IQP-G-002AS) was shown to be effective and safe for weight loss in overweight and obese subjects. However, long-term effectiveness on maintenance of body weight loss has yet to be ascertained. Objective. To assess effect of Litramine on maintenance of body weight loss. Methods...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Obesity |
| Online Access: | http://dx.doi.org/10.1155/2015/953138 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545326747090944 |
|---|---|
| author | Barbara Grube Pee-Win Chong Felix Alt Ralf Uebelhack |
| author_facet | Barbara Grube Pee-Win Chong Felix Alt Ralf Uebelhack |
| author_sort | Barbara Grube |
| collection | DOAJ |
| description | Background. Litramine (IQP-G-002AS) was shown to be effective and safe for weight loss in overweight and obese subjects. However, long-term effectiveness on maintenance of body weight loss has yet to be ascertained. Objective. To assess effect of Litramine on maintenance of body weight loss. Methods. A double-blind, randomised, placebo-controlled trial on overweight and obese patients was conducted over two sites in Germany for 24 weeks. Subjects with documented previous weight loss of 3% over the last 3–6 months were randomised to groups given either Litramine (3 g/day) or a matching placebo. Primary endpoints were difference of mean body weight (kg) between baseline and end of study and maintenance of initially lost body weight in verum group, where maintenance is defined as ≤1% weight gain. Results. Subjects who were taking Litramine lost significantly more body weight compared to the subjects taking placebo who gained weight instead (-0.62±1.55 kg versus 1.62±1.48 kg, p<0.001). More importantly, 92% of subjects in Litramine group were able to maintain their body weight after initial weight loss, versus 25% in placebo group. No serious adverse events were reported throughout. Conclusion. Litramine is effective and safe for long-term body weight maintenance. Trial Registration. This trial is registered with Clinicaltrials.gov identifier: NCT01505387. |
| format | Article |
| id | doaj-art-b3c64db189954e9b9071624a348bbf78 |
| institution | Kabale University |
| issn | 2090-0708 2090-0716 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Obesity |
| spelling | doaj-art-b3c64db189954e9b9071624a348bbf782025-02-03T07:26:15ZengWileyJournal of Obesity2090-07082090-07162015-01-01201510.1155/2015/953138953138Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled StudyBarbara Grube0Pee-Win Chong1Felix Alt2Ralf Uebelhack3Practice for General Medicine, Kurfürstendamm 157/158, 10709 Berlin, GermanyZaluvida Corporate Sdn Bhd, E-16 Plaza Mont Kiara, 2 Jalan Kiara, 50480 Kuala Lumpur, MalaysiaAnalyze & Realize GmbH, Waldseeweg 6, 13467 Berlin, GermanyAnalyze & Realize GmbH, Weißenseer Weg 111, 10369 Berlin, GermanyBackground. Litramine (IQP-G-002AS) was shown to be effective and safe for weight loss in overweight and obese subjects. However, long-term effectiveness on maintenance of body weight loss has yet to be ascertained. Objective. To assess effect of Litramine on maintenance of body weight loss. Methods. A double-blind, randomised, placebo-controlled trial on overweight and obese patients was conducted over two sites in Germany for 24 weeks. Subjects with documented previous weight loss of 3% over the last 3–6 months were randomised to groups given either Litramine (3 g/day) or a matching placebo. Primary endpoints were difference of mean body weight (kg) between baseline and end of study and maintenance of initially lost body weight in verum group, where maintenance is defined as ≤1% weight gain. Results. Subjects who were taking Litramine lost significantly more body weight compared to the subjects taking placebo who gained weight instead (-0.62±1.55 kg versus 1.62±1.48 kg, p<0.001). More importantly, 92% of subjects in Litramine group were able to maintain their body weight after initial weight loss, versus 25% in placebo group. No serious adverse events were reported throughout. Conclusion. Litramine is effective and safe for long-term body weight maintenance. Trial Registration. This trial is registered with Clinicaltrials.gov identifier: NCT01505387.http://dx.doi.org/10.1155/2015/953138 |
| spellingShingle | Barbara Grube Pee-Win Chong Felix Alt Ralf Uebelhack Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study Journal of Obesity |
| title | Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study |
| title_full | Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study |
| title_fullStr | Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study |
| title_full_unstemmed | Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study |
| title_short | Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study |
| title_sort | weight maintenance with litramine iqp g 002as a 24 week double blind randomized placebo controlled study |
| url | http://dx.doi.org/10.1155/2015/953138 |
| work_keys_str_mv | AT barbaragrube weightmaintenancewithlitramineiqpg002asa24weekdoubleblindrandomizedplacebocontrolledstudy AT peewinchong weightmaintenancewithlitramineiqpg002asa24weekdoubleblindrandomizedplacebocontrolledstudy AT felixalt weightmaintenancewithlitramineiqpg002asa24weekdoubleblindrandomizedplacebocontrolledstudy AT ralfuebelhack weightmaintenancewithlitramineiqpg002asa24weekdoubleblindrandomizedplacebocontrolledstudy |